2025-11-10T17:47:59-05:00 2024-12-31 WITHUMSMITHBROWNPC 1800 TYSONS BLVD SUITE 800 TYSONS VA 22102 990 2024-01-01 042531031 National Foundation For Cancer Research % KWOK LEUNG NATI 3016541250 5515 Security Lane Suite 1105 Rockville MD 20852 SUJUAN BA PRESIDENT & CEO 3016541250 2025-11-10 true true THOMAS PARISI P00013287 3012726000 2024 2025-03-06 01:10:19Z SUJUAN BA 5515 SECURITY LANE SUITE 1105 Rockville MD 20852 11230864 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 7 7 16 70 0 0 8681414 10388208 0 0 370595 691486 110433 16002 9162442 11095696 3445964 3614953 0 0 1910593 2009945 31582 29984 1806312 4402392 4144208 9790531 9799090 -628089 1296606 10533674 12279522 2852963 3006290 7680711 9273232 X SEE SCHEDULE O false false 5045821 3614953 Scientific Advancement: In 2023-2024, NFCR funded 37 scientists conducting groundbreaking research across more than 15 cancer types. This investment fuels basic, translational, and clinical research, expanding the global knowledge base and accelerating new therapeutic approaches. Clinical Impact: NFCR-supported discoveries advanced 7 therapies into clinical trial phases (5 Phase 1, 2 Phase 2), bringing innovative treatments closer to patients in need. Innovation Translation: NFCR contributed to breakthroughs in liquid biopsy technologies for early detection and precision oncology approaches, supporting innovations that improve patient outcomes and inform prevention strategies. Public Health Outreach: In 2024, NFCR distributed over 250 Cancer Prevention Kits, directly reaching over 1000 individuals through about 100 community events nationwide. These resources empower the public to adopt cancer-preventive behaviors and pursue timely screenings. Marketing & Communications Impact: NFCR's marketing and communications strategies amplify the reach, engagement, and influence of our scientific funding and public health initiatives, ensuring that program results translate into broad awareness, donor action, and sustained mission support. Owned & social channels: NFCR runs an active content ecosystem, including a blog, and media gallery with two YouTube series (Making Sense of Science and Cancer-Fighting Lifestyle), the All Things CANCER podcast, and an email newsletter sign-up for ongoing education and donor stewardship. Public education assets: NFCR publishes accessible prevention resources, including the downloadable Cancer Prevention & Early Detection Kit and Cancer Screening Guidelines, which reinforce behavior change and early detection messaging. Thought leadership & convenings: The annual NFCR Global Summit & Award Ceremonies serve as a collaboration engine where "new partnerships form every year," expanding the impact of NFCR's science communications beyond owned channels. Fundraising communications tied to outcomes: Event communications (e.g., Daffodils & Diamonds) publicly report results linking storytelling to tangible support for research. Mission context for all outreach: NFCR consistently communicates scale and stewardship - $420M+ funded and 5.3M+ lifetime donors in progress/annual reports and "About" materials, anchoring all marketing in mission impact. Through global collaboration, NFCR is making unique impact on a new and accelerated path to cures. NFCR envisions a world without cancer! 2232674 NFCR provides the public with free materials containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message has been mailed annually to households, reaching over 235,000 email subscribers and tens of thousands of individuals through our social media channels (Twitter and Facebook) and through our website and blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. 7278495 true true false false false true false false false true true false false true true true false true false false true true true true true false false true true true false false false false false false false false true false false false false true true false false false true 29 0 true 16 true false false false false false true true false false false false false false false false false X 7 7 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KWOK LEUNG 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X SUJUAN BA PRESIDENT/CEO 40.0 0.0 X 462395 0 94834 KWOK LEUNG CFO/SECRETARY 40.0 0.0 X 231444 0 33999 BRIAN WACHTEL CHIEF DEV OFFICER/EXEC. DIR 40.0 0.0 X 166208 0 22547 ZETING WANG SENIOR DIR OF DIRECT RESPONSE 40.0 0.0 X 123693 0 12406 ALFRED SLANETZ CHAIR OF THE BOARD 5.0 0.0 X X 0 0 0 BRIAN LEYLAND-JONES TREASURER 2.0 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 1.5 0.0 X 0 0 0 KAREN BURKE DIRECTOR 1.0 0.0 X 0 0 0 FRANKLIN SALISBURY JR DIRECTOR (EFF 01/31/2024) 1.0 0.0 X 0 0 0 SILAS DEANE DIRECTOR (EFF 05/24/2024) 1.0 0.0 X 0 0 0 PADMAKUMAR KAIMAL DIRECTOR (EFF 05/24/2024) 1.0 0.0 X 0 0 0 LANCE KAWAGUCHI DIRECTOR (THRU 01/26/2024) 1.0 0.0 X 0 0 0 983740 0 163786 4 false true false MOORE A SERIES LLC 4200 PARLIAMENT PLACE SUITE 300 LANHAM MD 20706 CONSULTING & MNGT 326078 REDFIELD DIRECT LLC 11422 MIRACLE HILLS DR 450 OMAHA NE 68154 LABEL PRINTING 316313 CALMARK GROUP LLC 6755 SAYRE AVE BEDFORD PARK IL 60638 MAIL SHOP 310462 C2 IMAGING - VOMELA COMMERCIAL 8000 GRAINGER COURT SPRINGFIELD VA 22153 ENVELOPE PRINTING 249726 LARSEN MARKETING GROUP 6236 WILMETTE BURKE VA 22015 CONSULTING 203108 7 37445 353871 9996892 129870 10388208 0 292097 0 292097 0 826 826 0 0 0 478861 79472 399389 399389 399389 34704 353871 55696 -20992 -20992 0 0 0 0 0 0 MAILING LIST RENTALS 541800 36168 36168 36168 11095696 0 707488 3357035 3357035 222918 222918 35000 35000 0 825987 614946 122708 88333 0 953675 654490 99150 200035 77115 51727 6601 18787 54639 35110 8088 11441 98529 69922 12162 16445 0 19500 19500 54833 54833 0 29984 29984 44973 44973 523614 237748 207004 78862 41805 16502 23538 1765 95858 30866 57808 7184 556264 261790 4947 289527 0 236951 164215 34317 38419 27231 8146 14709 4376 0 124320 124320 0 0 7022 4984 870 1168 20307 14414 2515 3378 DIRECT MAIL PROGRAMS 2272611 1309186 963425 LOCK BOX SERVICE 91503 56254 35249 PROCESS FEES-LIST SALES 12855 7947 4908 MISCELLANEOUS FUNDRAISING 14561 975 560 13026 9799090 7278495 714283 1806312 X 1337 2799 1752406 1990757 0 0 51727 20803 0 0 0 0 0 0 0 0 373197 199259 230904 213386 20192 17518 4826460 6479022 200442 200442 0 0 0 0 3307913 3368922 10533674 12279522 722035 813237 1393836 1681280 135 135 0 0 0 0 0 0 0 0 0 0 736957 511638 2852963 3006290 X 4299106 5659360 3381605 3613872 7680711 9273232 10533674 12279522 1296606 295915 X false true X true false X 10990906 9444496 8181991 8681414 10388208 47687015 0 0 10990906 9444496 8181991 8681414 10388208 47687015 641352 47045663 222444 276898 202224 252937 292923 1247426 0 2859 0 1186 0 4045 192317 135298 86699 102377 36168 552859 49491345 0.95058 0.95119 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 3040 true true 6322361 3667989 265029 3575105 6680274 6205432 3405566 62641 3351278 6322361 7190200 2206693 -605813 2585648 6205432 7784738 3290006 213641 4098185 7190200 7915837 3260266 193223 3584588 7784738 0.45860 0.36290 0.17850 false false 26890 20665 6225 158632 149578 9054 45382 43143 2239 17518 AMOUNT HELD IN TRUST BY OTHERS 2923041 RIGHT OF USE ASSET 445881 3368922 0 LEASE LIABILITY 511638 511638 X PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FASB ASC 740 FOOTNOTE: The Foundation has been recognized by the Internal Revenue Service ("IRS") as exempt from income tax under Internal Revenue Code Section 501(c)(3) and related state statutes, except for income tax on unrelated business income, if any. It qualifies as a public charity under Section 509(a)(1). The Darwin Foundation has been recognized by the IRS as exempt from income tax under Section 501(c)(3) and related state statutes, except for income tax on unrelated business income, if any. It is a supporting organization to NFCR under Section 509(a)(3). GAAP requires management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2024 there are no uncertain positions taken or expected to be taken that would require recognition in the consolidated financial statements. The Foundation is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods. In addition, there have been no tax related interest or penalties for the periods presented in these consolidated financial statements. Should such penalties and interest be incurred, the Foundation's policy is to recognize them as general and administrative expenses on the consolidated statements of activities and changes in net assets. true Europe (Including Iceland and Greenland) 0 0 Grantmaking 30000 East Asia and the Pacific 0 0 Grantmaking 5000 0 0 0 0 35000 35000 Europe (Including Iceland and Greenland) Research 25000 WIRE 0 1 RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 CHECK RESEARCH REVIEW East Asia and the Pacific 1 5000 CHECK false false false false false false PART I, LINE 2 Procedure for monitoring use of grants outside USA: Grant and Contract recipients are required to submit quarterly expenditure reports and annual progress reports to NFCR. X X X X X X true AMERGENT INC 9 CENTENNIAL DR PEABODY MA 01960 direct mail counsel false 3474599 29984 3444615 3474599 29984 3444615 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY PLAY FOR A CURE 171043 171043 4430 DAFFODILS & DIA 104704 70000 34704 4948 15666 14294 9 112828 112828 16358 388575 353871 34704 4948 15666 35082 55696 -20992 true CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 61088 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 152340 RESEARCH CONTRACTS UNIVERSITY OF CALIFORNIA AT SAN DIEGO PO BOX 12385 LA JOLLA CA 92093 943067788 501(c)(3) 62257 RESEARCH CONTRACTS YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(c)(3) 230000 RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 50236 RESEARCH CONTRACTS WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE BOX 164 NEW YORK NY 10065 150532082 501(c)(3) 16924 RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 211120 RESEARCH CONTRACTS AIM HI ACCELERATOR FUND 5515 SECURITY LN 1105 ROCKVILLE MD 20852 824322538 501(C)(3) 870000 collaboration MASSACHUSETTS GENERAL HOSPITAL P O BOX 414876 BOSTON MA 02241 041564655 501(C)(3) 352092 RESEARCH CONTRACTS OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SW PARK RD PORTLAND OR 97239 237083114 501(C)(3) 120247 RESEARCH CONTRACTS JOHNS HOPKINS UNIVERSITY 3400 N CHARLES ST BALTIMORE MD 21218 520595110 501(C)(3) 95296 RESEARCH CONTRACTS UNIVERSITY OF WASHINGTON 509 OLIVE WAY SEATTLE WA 98101 916001537 501(C)(3) 29244 RESEARCH CONTRACTS NEW YORK UNIVERSITY GROSSMAN SCHOOL MED 1 PARK AVE 6TH FLOOR NEW YORK NY 10016 135562308 501(C)(3) 147983 RESEARCH CONTRACTS UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CTR 660 PARRINGTON OVAL RM 119 NORMAN OK 73019 736091755 501(C)(3) 56609 RESEARCH CONTRACTS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 501(C)(3) 140000 RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(C)(3) 200000 RESEARCH CONTRACTS THOMAS JEFFERSON CANCER CENTER 1101 MARKET ST PHILADELPHIA PA 19107 231352651 501(C)(3) 5912 RESEARCH CONTRACTS HENRY FORD HEALTH SYSTEM 2799 WEST GRAND BLVD DETROIT MI 48202 381357020 501(C)(3) 140000 RESEARCH CONTRACTS UNIVERSITY OF ROCHSTER 910 GENESEE STE 200 ROCHESTER NY 14611 160743209 501(C)(3) 140000 RESEARCH CONTRACTS COLUMBIA UNIVERSITY 622 W 113TH ST NEW YORK NY 10025 135598093 501(C)(3) 250000 RESEARCH CONTRACTS 20 0 CANCER RESEARCH 4 137918 RESEARCH REVIEW 2 55000 RESEARCH AWARD 1 30000 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X X X false false false false false false false true false SUJUAN BA PRESIDENT/CEO 461207 0 0 0 1188 0 69000 0 25834 0 557229 0 0 0 KWOK LEUNG CFO/SECRETARY 226658 0 2500 0 2286 0 33999 0 0 0 265443 0 0 0 BRIAN WACHTEL CHIEF DEV OFFICER/EXEC. DIR 164063 0 1875 0 270 0 22547 0 0 0 188755 0 0 0 SCHEDULE J, PART I, LINE 7 BONUSES PAID TO KWOK LEUNG, BRIAN WACHTEL, AND ZETING WANG ARE DETERMINED ON AN ANNUAL BASIS BY THE BOARD AND/OR MANAGEMENT OF NFCR. X 4 129870 stock market value false true false PART III, LINE 1 - ORGANIZATION'S MISSION: The National Foundation for Cancer Research (NFCR) is a leading public charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, cures for cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $415 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR is committed to fighting cancer by funding high-risk, high-impact, and potentially high-reward discoveries in the labs and transforming them into life-saving treatments for cancer patients. Through global collaboration, NFCR is making unique impacts on new, accelerated paths to a cure. NFCR envisions a world without cancer! PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE 19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. PART IX, LINE 26, JOINT COSTS ALLOCATION: NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 50 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY POSTAL MAIL, EMAIL, PHONE, WEBSITE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT ABOUT CANCER AND UPHOLD ITS MISSION, AND AT THE SAME TIME TO PROVIDE FUNDRAISING OPPORTUNITIES. THE COSTS RELATED TO THESE JOINT ACTIVITIES ARE ALLOCATED, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. DARWIN FOUNDATION 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 371473821 CANCER RSRCH DC 501(C)3 509(A)(3) NFCR true false false false false false false false false false false false false false false false false false false false